MTOR and hereditary disease: The mechanistic target of rapamycin (mTOR) pathway diseases (Table 1) is a group of rare early-onset, hard-to-treat genetic diseases with symptoms ranging from benign tumours in multiple organs to brain malformations causing epilepsy, each of which is managed in disconnected medical disciplines (Fig. 1).